Antibiotics Market Size ,Share ,Industry Growth ,Key Players And Forecast To 2026| Grand View Research, Inc
“The global antibiotics market size was valued at USD 45.31 billion in 2018 and is projected to expand at a CAGR of 4.0% over the forecast period .�
The global antibiotics market size is expected to reach USD 62.06 billion by 2025 expanding at a CAGR of 4.0%, according to a new report by Grand View Research, Inc. Rising prevalence of infectious diseases, especially in developing regions like Asia Pacific and Middle East, is anticipated to contribute to the market growth. More than 15.0% of the deaths in children below the age of five years, are estimated to be due to pneumonia and according to the statistics provided by the WHO about 9.2 million deaths were recorded in 2015. Similar to tuberculosis, the disease is highly prevalent in the South Asian and Sub-Saharan regions. Currently, the required antibiotic treatment is available only to one-third of the infected population, thereby increasing the disease burden. Government reforms specific to antibiotics, such as the Generating Antibiotics Incentives Now (GAIN) Act in U.S., are projected to help boost the market growth over the forecast period. This is further expected to facilitate development of advanced drugs. According to an article published by the Pew Charitable Trusts, nearly 30% of the outpatient oral antibiotics prescriptions are unnecessary and majority of these are prescribed for disease conditions, such as non-bacterial infections and acute respiratory conditions, against which antibiotics are not significantly effective. Such indiscriminate use of antibiotics is anticipated to increase the risk of difficult-to-treat antibioticresistant infections, thereby increasing the economic burden.
Browse Details of Report @ www.grandviewresearch.com/industry-analysis/antibiotic-market
Follow Us:
Further key findings from the study suggest:
RNA and folic acid synthesis inhibitors are anticipated to witness healthy CAGRs over the forecast period
Development of several antiviral drugs, which inhibit transcription and reverse transcription process are anticipated to support this growth
Asia Pacific is anticipated to witness the highest CAGR over the forecast period on account of large population base, prevalence of infectious diseases, regulation reforms, and wide usage of generic medicine
Latin America, especially Brazil, is also projected to exhibit remunerative growth due to strong growth in pharmaceutical sector
Outbreak of certain viruses, such as Ebola, in African region contributed to the region’s growth Some of the key companies in the market are Pfizer, Inc; Janssen Pharmaceuticals; Abbott laboratories; GlaxoSmithKline plc; Sanofi S.A.; Novartis AG; Bayer AG; Bristol Myers Squibb Company; Eli Lilly & Company, and Astellas Pharma, Inc.
Grand View Research has segmented the global antibiotics market on the basis of action mechanism, drug class, and region: Antibiotics Action Mechanism Outlook (Revenue, USD Million, 2015 - 2026) Cell Wall Synthesis Inhibitors
Protein Synthesis Inhibitors
DNA Synthesis Inhibitors
RNA Synthesis Inhibitors
Mycolic Acid Inhibitors
Antibiotics Drug Class Outlook (Revenue, USD Million, 2015 - 2026) Cephalosporin
Penicillin
Fluoroquinolone
Macrolides
Carbapenems
Aminoglycosides
Sulfonamide
Other
Antibiotics Regional Outlook (Revenue, USD Million, 2015 - 2026) North America o
Follow Us:
U.S.
o
Canada
Europe o
Germany
o
U.K.
o
France
o
Italy
o
Spain
Asia Pacific o
China
o
Japan
o
India
o
Thailand
o
South Korea
Latin America o
Brazil
o
Mexico
o
Argentina
o
Colombia
MEA o
South Africa
o
Saudi Arabia
o
UAE
Browse Related Category Reports @ www.grandviewresearch.com/industry/pharmaceuticals Table of Content of Antibiotics Market Chapter 1. Methodology and Scope 1.1. Market segmentation & scope 1.2. Information procurement 1.2.1. Purchased database 1.2.2. GVR’s internal database
Follow Us:
1.2.3. Secondary sources & third-party perspectives 1.2.4. Primary research 1.3. Information analysis 1.3.1. Data analysis models 1.4. Market formulation & data visualization 1.5. Data validation & publishing Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.3. Competitive Insights Chapter 3. Antibiotics Market Variables, Trends & Scope 3.1. Market Lineage outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Penetration & Growth Prospect Mapping 3.3. Product Pipeline Analysis, by Stage 3.4. User perspective analysis 3.4.1. Consumer Behavior Analysis 3.4.2. Market Influencer Analysis 3.5. List of Key End-users, by region / by product / by country 3.6. Regulatory Framework 3.6.1. Reimbursement framework 3.6.2. Standards & Compliances 3.7. Market Dynamics 3.7.1. Market Driver Analysis 3.7.2. Development of advanced products 3.7.3. Increasing prevalence of` infectious diseases 3.7.4. Rising collaborative development efforts 3.7.5. Market Restraint Analysis 3.7.6. Uncertain regulatory policies 3.7.7. High R & D cost 3.7.8. Development of resistance against antibiotics
Follow Us:
3.7.9. Industry Challenges 3.7.10. Increasing resistance to antibiotics. 3.8. Antibiotics: Market Analysis Tools 3.8.1. Industry Analysis - Porter’s 3.8.1.1. Supplier Power: (Low) 3.8.1.2. Buyer Power: (Moderate) 3.8.1.3. Substitution Threat: (Moderate) 3.8.1.4. Threat from new entrant: (Moderate) 3.8.1.5. Competitive rivalry: (High) 3.8.2. PESTEL Analysis 3.8.2.1. Political Landscape 3.8.2.2. Environmental Landscape 3.8.2.3. Social Landscape 3.8.2.4. Technology Landscape 3.8.2.5. Legal Landscape 3.8.3. Major Deals & Strategic Alliances Analysis 3.8.3.1. Joint Ventures 3.8.3.2. Mergers & Acquisitions 3.8.3.3. Licensing & Partnership 3.8.3.4. Technology Collaborations 3.8.3.5. Strategic Divestments 3.8.4. Market Entry Strategies Chapter 4. Antibiotics Market: Segment Analysis, By Action Mechanism, 2015 - 2026 (USD Million) 4.1. Definitions & Scope 4.2. Action mechanism market share analysis, 2018 & 2026 4.3. Segment Dashboard 4.4. Global Antibiotics Market, by Action Mechanism, 2015 to 2026 4.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following 4.5.1. Cell Wall Synthesis Inhibitors 4.5.2. Protein Synthesis Inhibitors 4.5.3. DNA Synthesis Inhibitors 4.5.4. RNA Synthesis Inhibitors
Follow Us:
4.5.5. Mycolic Acid Inhibitors Chapter 5. Antibiotics Market: Segment Analysis, By Drug Class, 2015 - 2026 (USD Million) 5.1. Definitions & Scope 5.2. Action mechanism market share analysis, 2018 & 2026 5.3. Segment Dashboard 5.4. Global Antibiotics Market, by Drug Class, 2015 to 2026 5.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following 5.5.1. Cephalosporin 5.5.2. Penicillin 5.5.3. Fluoroquinolones 5.5.4. Macrolides 5.5.5. Carbapenem 5.5.6. Aminoglycosides 5.5.7. Sulfonamides 5.5.8. Other Chapter 6. Antibiotics Market: Regional Market Analysis, 2015 - 2026 (USD Million) 6.1. Definitions & Scope 6.2. Regional market share analysis, 2018 & 2026 6.3. Regional Market Dashboard 6.4. Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends) 6.5. Regional Market Share and Leading Players, 2018 6.5.1. North America 6.5.2. Europe 6.5.3. Asia Pacific 6.5.4. Latin America 6.5.5. Middle East & Africa 6.6. SWOT Analysis, by Factor (Political & Legal, Economic And Technological) 6.6.1. North America 6.6.2. Europe 6.6.3. Asia Pacific 6.6.4. Latin America 6.6.5. Middle East & Africa
Follow Us:
6.7. Market Size, & Forecasts, and Trend Analysis, 2018 to 2025: 6.8. North America 6.8.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million) 6.8.2. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.8.3. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.8.4. U.S. 6.8.4.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.8.4.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.8.5. Canada 6.8.5.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.8.5.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.9. Europe 6.9.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million) 6.9.2. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.9.3. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.9.4. Germany 6.9.4.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.9.4.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.9.5. U.K. 6.9.5.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.9.5.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.9.6. France 6.9.6.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.9.6.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.9.7. Italy 6.9.7.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.9.7.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.9.8. Spain 6.9.8.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.9.8.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.10. Asia Pacific 6.10.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
Follow Us:
6.10.1.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.10.1.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.10.2. China 6.10.2.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.10.2.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.10.3. Japan 6.10.3.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.10.3.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.10.4. India 6.10.4.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.10.4.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.10.5. Thailand 6.10.5.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.10.5.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.10.6. South Korea 6.10.6.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.10.6.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.11. Latin America 6.11.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million) 6.11.2. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.11.3. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.11.4. Brazil 6.11.4.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.11.4.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.11.5. Mexico 6.11.5.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.11.5.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.11.6. Argentina 6.11.6.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.11.6.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.11.7. Columbia 6.11.7.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million)
Follow Us:
6.11.7.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.12. Middle East and Africa 6.12.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million) 6.12.2. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.12.3. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.12.4. South Africa 6.12.4.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.12.4.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.12.5. Saudi Arabia 6.12.5.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.12.5.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) 6.12.6. UAE 6.12.6.1. Market estimates and forecast, by action mechanism, 2015 - 2026 (USD Million) 6.12.6.2. Market estimates and forecast, by drug class, 2015 - 2026 (USD Million) Chapter 7. Antibiotics Market - Competitive Analysis 7.1. Recent developments & impact analysis, by key market participants 7.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players) 7.3. Vendor Landscape 7.3.1. List of key distributors and channel partners 7.3.2. Key customers 7.3.3. Key company market share analysis, 2018 7.4. Public Companies 7.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances) 7.4.2. Company Market Share/Ranking, by region 7.4.3. Competitive Dashboard Analysis 7.4.3.1. Market Differentiators 7.4.3.2. Synergy Analysis: Major Deals & Strategic Alliances 7.5. Private Companies 7.5.1. List of key emerging companies’ /technology disruptors/innovators 7.5.2. Funding Outlook (Optional) 7.5.3. Regional network map
Follow Us:
7.5.4. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience) 7.6. Supplier Ranking 7.7. Key companies profiled 7.7.1. Pfizer, Inc. 7.7.1.1. Company Overview 7.7.1.2. Financial Performance 7.7.1.3. Product Benchmarking 7.7.1.4. Strategic Initiatives 7.7.2. Janssen Pharmaceuticals. 7.7.2.1. Company Overview 7.7.2.2. Financial Performance 7.7.2.3. Product Benchmarking 7.7.2.4. Strategic Initiatives 7.7.3. Abbott 7.7.3.1. Company Overview 7.7.3.2. Financial Performance 7.7.3.3. Product Benchmarking 7.7.3.4. Strategic Initiatives 7.7.4. GlaxoSmithKline plc. 7.7.4.1. Company Overview 7.7.4.2. Financial Performance 7.7.4.3. Product Benchmarking 7.7.4.4. Strategic Initiatives 7.7.5. Sanofi. 7.7.5.1. Company Overview 7.7.5.2. Financial Performance 7.7.5.3. Product Benchmarking 7.7.5.4. Strategic Initiatives 7.7.6. Novartis AG. 7.7.6.1. Company Overview 7.7.6.2. Financial Performance
Follow Us:
7.7.6.3. Product Benchmarking 7.7.6.4. Strategic Initiatives 7.7.7. Bayer AG. 7.7.7.1. Company Overview 7.7.7.2. Financial Performance 7.7.7.3. Product Benchmarking 7.7.7.4. Strategic Initiatives 7.7.8. Bristol-Myers Squibb Company. 7.7.8.1. Company Overview 7.7.8.2. Financial Performance 7.7.8.3. Product Benchmarking 7.7.8.4. Strategic Initiatives 7.7.9. Eli Lilly and Company. 7.7.9.1. Company Overview 7.7.9.2. Financial Performance 7.7.9.3. Product Benchmarking 7.7.9.4. Strategic Initiatives 7.7.10. Astellas Pharma, Inc. 7.7.10.1. Company Overview 7.7.10.2. Financial Performance 7.7.10.3. Product Benchmarking 7.7.10.4. Strategic Initiatives Chapter 8. KOL Commentary Chapter 9. Recommendations
Follow Us:
About Us: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email: sales@grandviewresearch.com For More Information: http://www.grandviewresearch.com
Follow Us:
Follow Us: